GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bioject Medical Technologies Inc (OTCPK:BJCT) » Definitions » Asset Turnover

Bioject Medical Technologies (Bioject Medical Technologies) Asset Turnover : 0.66 (As of Sep. 2011)


View and export this data going back to . Start your Free Trial

What is Bioject Medical Technologies Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Bioject Medical Technologies's Revenue for the three months ended in Sep. 2011 was $3.14 Mil. Bioject Medical Technologies's Total Assets for the quarter that ended in Sep. 2011 was $4.75 Mil. Therefore, Bioject Medical Technologies's Asset Turnover for the quarter that ended in Sep. 2011 was 0.66.

Asset Turnover is linked to ROE % through Du Pont Formula. Bioject Medical Technologies's annualized ROE % for the quarter that ended in Sep. 2011 was 191.23%. It is also linked to ROA % through Du Pont Formula. Bioject Medical Technologies's annualized ROA % for the quarter that ended in Sep. 2011 was 33.49%.


Bioject Medical Technologies Asset Turnover Historical Data

The historical data trend for Bioject Medical Technologies's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioject Medical Technologies Asset Turnover Chart

Bioject Medical Technologies Annual Data
Trend Mar01 Mar02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 0.90 0.94 1.21 1.25

Bioject Medical Technologies Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.45 0.46 0.54 0.66

Competitive Comparison of Bioject Medical Technologies's Asset Turnover

For the Medical Instruments & Supplies subindustry, Bioject Medical Technologies's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioject Medical Technologies's Asset Turnover Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bioject Medical Technologies's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Bioject Medical Technologies's Asset Turnover falls into.



Bioject Medical Technologies Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Bioject Medical Technologies's Asset Turnover for the fiscal year that ended in Dec. 2010 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2010 )/( (Total Assets (A: Dec. 2009 )+Total Assets (A: Dec. 2010 ))/ count )
=5.577/( (5.256+3.67)/ 2 )
=5.577/4.463
=1.25

Bioject Medical Technologies's Asset Turnover for the quarter that ended in Sep. 2011 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2011 )/( (Total Assets (Q: Jun. 2011 )+Total Assets (Q: Sep. 2011 ))/ count )
=3.144/( (4.882+4.624)/ 2 )
=3.144/4.753
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Bioject Medical Technologies  (OTCPK:BJCT) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Bioject Medical Technologies's annulized ROE % for the quarter that ended in Sep. 2011 is

ROE %**(Q: Sep. 2011 )
=Net Income/Total Stockholders Equity
=1.592/0.8325
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(1.592 / 12.576)*(12.576 / 4.753)*(4.753/ 0.8325)
=Net Margin %*Asset Turnover*Equity Multiplier
=12.66 %*2.6459*5.7093
=ROA %*Equity Multiplier
=33.49 %*5.7093
=191.23 %

Note: The Net Income data used here is four times the quarterly (Sep. 2011) net income data. The Revenue data used here is four times the quarterly (Sep. 2011) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Bioject Medical Technologies's annulized ROA % for the quarter that ended in Sep. 2011 is

ROA %(Q: Sep. 2011 )
=Net Income/Total Assets
=1.592/4.753
=(Net Income / Revenue)*(Revenue / Total Assets)
=(1.592 / 12.576)*(12.576 / 4.753)
=Net Margin %*Asset Turnover
=12.66 %*2.6459
=33.49 %

Note: The Net Income data used here is four times the quarterly (Sep. 2011) net income data. The Revenue data used here is four times the quarterly (Sep. 2011) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Bioject Medical Technologies Asset Turnover Related Terms

Thank you for viewing the detailed overview of Bioject Medical Technologies's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioject Medical Technologies (Bioject Medical Technologies) Business Description

Traded in Other Exchanges
N/A
Address
Bioject Medical Technologies Inc commenced operations in 1985 and is a developer and manufacturer of needle-free injection therapy systems (NFITS). The Companys long-term goal is to become supplier of needle-free injection systems to the pharmaceutical and biotechnology industries. It focused its business development efforts on new and existing licensing and supply agreements with pharmaceutical and biotechnology companies, as well as numerous research agreements that could guide to long-term agreements. The Companys pipeline of prospective new partnerships remains active. It is also actively pursuing additional opportunities both domestically and overseas as it expands its current product line. The Companys Biojector 2000 system (B2000) consists of two components: a hand-held, reusable jet injector and a sterile, single-use, disposable plastic syringe capable of delivering variable doses of medication up to 1.0 mL. Drug Reconstitution System - The needle-free drug reconstitution system allows for the transfer of diluents to reconstitute powdered medications into liquid form and withdrawal of liquid medication into a syringe without the use of a needle. Vitajet - The Vitajet is also composed of two components, a portable injector unit and a disposable syringe. It is smaller and lower in cost than other products in its needle-free offering. ZetaJet - The ZetaJet is Biojects latest advance in needle-free delivery systems. It consists of two components, the portable injector and an auto-disabling disposable syringe. The medical equipment market is very competitive. Bioject Medical Technologies has two patents: Biojector 2000 and Vitajet. The Companys products and manufacturing operations are subject to extensive government regulations, both in the U.S. and abroad. In the U.S., the Food and Drug Administration (FDA) administers the Federal Food, Drug and Cosmetic Act (FFDCA) and has adopted regulations to administer the FFDCA.
Executives
James C Gale director 152 W 57TH STREET, 19TH FLOOR, NEW YORK NY 10019
Sanders Morris Harris Inc/fa 10 percent owner, other: See General Remarks 600 TRAVIS, SUITE 5900, HOUSTON TX 77002
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Edward L Flynn director, 10 percent owner 211 SOMERVILLE ROAD RTE 202N, BEDMINISTER NJ 07921
Life Sciences Opportunities Fund Ii Lp 10 percent owner 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Lof Partners Llc other: See general remarks 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Life Sciences Opportunities Fund Instittutional Ii Lp 10 percent owner 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Randal D Chase director 28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7
Brigid Makes director 20245 SW 95TH AVENUE, TUALATIN OR 97062
J Michael Redmond officer: Sr. VP Bus Dev. 10 CANTERBURY ROAD, WINDHAM NH 03087
Elan Corp Plc 10 percent owner TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000
Elan International Services Ltd 10 percent owner C/O TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN L2 2
Elan Pharmaceutical Investments Ltd 10 percent owner 102 ST JAMES COURT, FIETSS SMITH FL BERM D0 9999999999
John P Gandolfo officer: CFO 62 TERRACE ROAD, WAYNE NJ 07470
Grace K Fey director 1210 CROMWELL ROAD, HALIFAX NOVA SCOTIA A5 B3H4L2

Bioject Medical Technologies (Bioject Medical Technologies) Headlines

No Headlines